Document Type : Case Report

Authors

Department of Neurology, Coimbatore Medical College Hospital, Coimbatore, India

Abstract

Introduction: Phenytoin and sodium valproate are widely used antiepileptics with well documented side effects profile. However diffuse calvarial thickening and lingual dystonia with the use of phenytoin and sodium valproate respectively is extremely rare. This case underscores the importance of recognizing rare side effects in patients on long term anticonvulsant therapy.
Case presentation: We present two cases of seizure disorder patients who were on first line antiepileptics phenytoin and sodium valproate developed uncommon side effects of diffuse calvarial thickening and lingual dystonia respectively during their follow up. CASE 1: 15 year old boy a case of refractory epilepsy with global developmental delay who was on multiple antiepileptics including phenytoin was admitted with breakthrough seizures. Patient had gum hypertrophy and serum phenytoin level was elevated and CT brain showed diffuse calvarial thickening, the offending drug was stopped. CASE 2: 45 year old female a case of idiopathic generalised epilepsy was started on sodium valproate for seizure control and she developed lingual dystonia during follow up. Having ruled out the secondary causes of dystonia the possible temporal association between the use of sodium valproate and lingual dystonia. Patient improved after stopping the use of sodium valproate.
Discussion: This case report highlights two rare adverse effects associated with commonly used anticonvulsants emphasizing the need for heightened clinical vigilance.Early identification is essential for better clinical outcome.
Conclusion: Long term use of phenytoin and sodium valproate can lead to rare but significant adverse effects such as calvarial thickening and lingual dystonia. 

Keywords

Main Subjects

1. Chow KM, Szeto CC. Cerebral atrophy and skull thickening due to chronic phenytoin therapy. CMAJ. 2007 Jan 30; 176(3):321-3. doi: 10.1503/cmaj.061171. PMID: 17261827; PMCID: PMC1780093.
2. Zhou DJ, Pavuluri S, Snehal I, Schmidt CM, Situ-Kcomt M, Taraschenko O. Movement disorders associated with antiseizure medications: A systematic review. Epilepsy Behav. 2022 Jun; 131(Pt A):108693. doi: 10.1016/j.yebeh.2022.108693. Epub 2022 Apr 25. PMID: 35483204; PMCID: PMC9596228.
3. Kattan KR. Calvarial thickening after Dilantin medication. Am J Roentgenol Radium Ther Nucl Med. 1970 Sep; 110(1):102-5. doi: 10.2214/ajr.110.1.102. PMID: 5459522.
4. Patil MM, Sahoo J, Kamalanathan S, Pillai V. Phenytoin Induced Osteopathy -Too Common to be Neglected. J Clin Diagn Res. 2015 Nov;9(11):OD11-2. doi: 10.7860/JCDR/2015/15224.6820. Epub 2015 Nov 1. PMID: 26674262; PMCID: PMC4668458.
5. Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutr Metab (Lond). 2006 Sep 6; 3:36. doi: 10.1186/1743-7075-3-36. PMID: 16956398; PMCID: PMC1586194.
6. Rissardo JP, Caprara ALF, Durante Í. Valproate-associated Movement Disorder: A Literature Review. Prague Med Rep. 2021; 122(3):140-180. doi: 10.14712/23362936.2021.14. PMID: 34606429.